OUTREACH AGENDA

外展议程

• 批准号: 6267810
• 负责人: Lawrence JOSEPH WHEAT
• 金额: $ 14.39万
• 依托单位: INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-01-01 至 1998-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6267810
• 关键词: AIDS; AIDS therapy; African American; HIV infections; Hispanic Americans; Native Americans; clinical research; clinical trial phase I; cooperative study; female; human subject; human therapy evaluation; medical outreach /case finding; racial /ethnic difference; women's health

The progressive loss of CD4 lymphocytes correlates with the progression of HIV infection to AIDS. At present, other correlates of disease progression are lacking. Thus, routine immunophenotyping of HIV-infected individuals is justified. Unfortunately, analysis of other lymphocyte markers has not been sufficiently done to determine if they also can predict changes in the course of the disease. The immune system is a complex interaction of many cell types. A progressive decline in the CD4 lymphocyte compartment is likely to cause shifts in the proportions of other lymphocyte subsets. The question arises as to whether changes in other lymphocyte surface antigens correlate with disease progression and more ideally, stabilize or revert in response to efficacious drug therapy. In order to investigate this issue, single color immunofluorescence technology had to develop a dual color capability. With the use of 2-color immunofluorescence, some activation and differentiation markers on lymphocyte subset cells showed promise of being good correlates of disease progression. However, these markers were not investigated in the context of clinical trials to assess drug effectiveness. A major reason was the cost and time required to analyze an extensive panel of 2-color profile tubes. Recently a third fluorochrome for routine 3-color immunofluorescence has become commercially available. The proposed study hopes to utilize this newest technology to consolidate a number of 2-color profile tubes into a more limited panel of 3-color profile tubes. This would allow a more manageable evaluation of clinical specimens. In addition, combinations of 3 discrete antibodies to pinpoint a particular subpopulation of lymphocytes can now be routinely investigated. One of the goals of this research will be to validate and justify the switch from routine 2-color to 3-color analysis. This will enable a more aggressive analysis of lymphocytes from individuals enrolled in ACTG clinical trials using an expanded panel of 3-color analysis tubes. It is hoped that in the subsequent years of this project, routine 3-color immunophenotyping will identify and validate changes in lymphocyte subset markers that correlate with HIV disease progression and/or drug efficacy.

CD 4淋巴细胞的进行性丢失与肿瘤的进展相关。 艾滋病病毒感染。 目前，疾病进展的其他相关因素 缺乏。 因此，HIV感染者的常规免疫分型 是有道理的 不幸的是，对其他淋巴细胞标志物的分析还没有 已经做了足够的工作，以确定他们是否也可以预测变化， 病程。 免疫系统是一个复杂的相互作用的许多 细胞类型。 CD 4淋巴细胞区室的进行性下降， 可能导致其他淋巴细胞亚群比例的变化。 的 问题是其他淋巴细胞表面抗原的变化 与疾病进展相关，更理想的是，稳定或恢复， 对有效药物治疗的反应。 为了调查这个问题， 单色免疫荧光技术不得不发展出双色免疫荧光技术， 能力。 通过使用双色免疫荧光， 淋巴细胞亚群细胞的分化标志物显示， 是疾病进展的良好相关因素。 然而，这些标记是 未在评估药物的临床试验背景下进行研究 有效性 一个主要的原因是分析一个 广泛的面板2色型材管。 最近第三种荧光染料 用于常规的三色免疫荧光已经可以在市场上买到。 这项拟议中的研究希望利用这项最新技术来巩固 将一些2色剖面管转换为更有限的3色面板 型材管。 这将使临床评估更易于管理。 标本 此外，3种离散抗体的组合可以精确定位 一个特定的淋巴细胞亚群现在可以被常规地 研究了 这项研究的目标之一将是验证和 证明从常规2色分析转换为3色分析的合理性。 这将 能够更积极地分析来自登记个体的淋巴细胞 在ACTG临床试验中使用了一组扩展的3色分析管。 希望在随后的几年里，这个项目，例行3色 免疫分型将鉴定和验证淋巴细胞亚群变化 与HIV疾病进展和/或药物功效相关的标志物。